secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277571
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca Q3 net loss $30.6M, cash $362M; patent issued for pan-RAS drug ERAS-0015
-------------------------------------------------------------------------------

- Net loss $30.6M ($0.11/sh) vs $31.2M in Q3 2024; R&D down to $22.5M from $27.6M.
- Cash $362.4M as of Sep 30, 2025 (down from $440.5M Dec 31); runway into H2 2028.
- U.S. composition of matter patent issued for ERAS-0015 covering composition through Sep 2043.
- Promoted Robert Shoemaker, Ph.D., from SVP research to chief scientific officer.
- Initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312525277571/0001193125-25-277571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312525277571/eras-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer